Introduction
============

An imbalance between energy intake and expenditure can result in excess triacylglycerol accumulation in adipose tissue, resulting in obesity ([@B10]). In morbid obesity an increased adipocyte number (hyperplasia) may occur through adipocyte differentiation of precursor cells present in adipose tissue ([@B35]; [@B40]). However, obesity is largely attributed to adipocyte hypertrophy that occurs when triacylglycerol synthesis exceeds breakdown (lipolysis), resulting in elevated triacylglycerol storage ([@B10]; [@B18]). Indeed, unlike triacylglycerol synthesis ([@B9]; [@B19]) that occurs at high levels in other tissues, lipolysis for the liberation of fatty acids that can then be used as an energy source by other tissues is unique to adipocytes ([@B10]). Thus, lipolysis and hyperplasia of adipocytes might be important factors in the development of obesity.

Lipolysis is one of the most important metabolic pathways regulating energy homeostasis and the pathogenesis of obesity ([@B59]). Lipolysis is governed by two major enzymes that are hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) ([@B3]). ATGL initiates lipolysis by cleaving the first FA from triglyceride (TG) and then HSL act on diacyglycerol (DAG), releasing two additional FAs and one glycerol molecule ([@B12]). Whereas HSL is present in the cytosol, ATGL is localized in the cytosol and also on lipid droplets ([@B59]; [@B25]).

Adipocytes are derived from mesenchymal stem cells, which have the potential to differentiate into myoblasts, chondroblasts, osteoblasts or adipocytes ([@B37]). Adipogenesis has been investigated extensively using 3T3-L1 cells. Adipocyte differentiation involves an elaborate network of transcription factors that regulate the expression of numerous genes responsible for the phenotype of mature adipocytes ([@B26]). Among the various transcription factors that promote preadipocyte differentiation and influence adipogenesis, peroxisome proliferator-activated receptor gamma (PPARγ) has been termed the \"master regulator of adipogenesis\" ([@B52]; [@B55]). Other adipogenic transcription factors include the CCAAT/enhancer binding proteins (C/EBPα) ([@B33]). They are necessary for the expression of adipocyte-specific genes, such as adiponectin ([@B56]).

Akt (protein kinase B, PKB), a PH domain containing serine/threonine kinase, regulates growth factor signaling to stimulate glucose uptake, glycogen synthesis ([@B7]) and protein synthesis by influencing the glycogen synthase kinase 3 (GSK3)α/β and tuberous sclerosis complex 2 (TSC2)-mTOR signaling pathways. Increased protein translation following Akt activation elicits skeletal muscle hypertrophy ([@B39]) and augments hepatic fatty acid oxidation with reduced fat accumulation ([@B17]). GSK3β, which influences insulin resistance, is phosphorylated and inhibited by Akt ([@B7]). Akt and GSK3β activity are reciprocally regulated in insulin resistance and obesity. Akt/mTOR activity is decreased ([@B44]; [@B11]) and GSK3β increased ([@B21]) in insulin-resistant tissues of aging and obese mice ([@B5]).

AMP-activated protein kinase (AMPK) activation leads to increased fat oxidation by the upregulation of the transcription factor NRF-1, which stimulates mitochondrial biogenesis and inhibits both lipolysis and lipogenesis, affecting directly the enzymes engaged in lipid metabolism and down-regulating PPARγ expression ([@B32]).

FTY720 (2-amino-2-\[2-(4-*n*-octylphenyl)ethyl\]-1, 3-propanediol hydrochloride) is synthetically derived from myriocin (ISP-1), a metabolite isolated from ascomycete, *Isaria sinclarii* ([@B24]). FTY720 is undergoing clinical trials for the treatment of immunologic disorders ([@B28]). FTY720-P is an analog of sphingosine 1-phosphate (S1P) that mediates its immunomodulatory effects primarily through G protein-coupled S1P receptors ([@B47]; [@B15]). It is a prodrug phosphorylated by type 2 sphingosine kinase to form FTY720-phosphate (FTY720-P) ([@B23]). The S1P~1~ receptor regulates the egress of lymphocytes from secondary lymphoid organs. By inducing the internalization and degradation of the S1P~1~ receptor, FTY720-P reduces circulating lymphocyte counts, and is therefore considered a promising therapy for immune disorders ([@B49]). However, other functions of FTY720 excluding immune modulation remain largely unknown. Recently, FTY720 was found to be able to prevent high-fat diet (HFD-induced weight gain, insulin resistance and adipose tissue inflammation in C57BL/6 mice ([@B22]). However, this previous study mainly focused on the effect of FTY720 on lymphocytes sequestration. The effect of FTY720 on adipocytes has not been studied, especially on adipogenesis and lipolysis, which are important on obesity development.

Investigation of the direct effect of FTY720 on adipocytes will provide some novel insights for additional inhibitory mechanism of FTY720 on obesity. We report that administration of FTY720 prevents obesity from high fat feeding by not only regulating lipolysis through HSL activation but also inhibiting adipogenesis *via* phosphorylation of Akt.

Results
=======

FTY720 administration mice are resistant to obesity
---------------------------------------------------

In this study, obesity was induced in normal mice by feeding a HFD for 10 weeks. After 3 weeks, mice fed the SD weighted 25.7 ± 0.6 *g* (*n* = 5), while control mice fed the HFD (HFD-CON) weighted 31.4 ± 2 *g* (*n* = 6). The respective weights at 8 weeks were 31.3 ± 1.5 *g* (*n* = 6) and 42.4 ± 1.7 *g* (*n* = 6). Compared with mice fed the SD, mice fed the HFD increased their body weight by 24.6% after 3 weeks of feeding and became 51.1% heavier after 8 weeks of feeding ([Figures 1A and 1B](#F1){ref-type="fig"}). Parallel to the body weight change, the weights of white adipose tissue (WAT) were significantly higher in obese mice than in normal mice at the end of 16 weeks (data not shown). FTY720 administration to mice fed the HFD (HFD-FTY720) effectively suppressed the increase in body weight compared with HFD-CON mice. After one week of injection, HFD-FTY720 mice weighted 33.8 ± 1.3 *g* (*n* = 6), while HFD-CON mice weighted 37.4 ± 1.9 *g* (*n* = 6). Compared with HFD mice, HFD-FTY720 mice displayed an 11% reduced body weight 1 week after the administration of FTY720. This ratio was maintained until the end of the experiment ([Figures 1C and 1D](#F1){ref-type="fig"}). The lower body weight of the mice administered FTY720 was largely accounted for by a reduction in WAT weight ([Figures 1F and 1G](#F1){ref-type="fig"}). At 16-weeks-of-age, HFD-FTY mice had effectively smaller WAT depots compared to HFD mice, with a combined WAT depot weight that was 20% lower ([Figure 1F](#F1){ref-type="fig"}). Body composition analysis indicated that FTY treatment decreased triacylglycerol content ([Figure 1H](#F1){ref-type="fig"}). Histological analysis showed that the gonadal WAT from HFD-CON contained significantly large adipocytes ([Figures 1I-1K](#F1){ref-type="fig"}, *P* \< 0.01) compared with SD, but FTY720 mice displayed considerably smaller adipocytes compared with those of HFD-CON mice ([Figures 1I-1K](#F1){ref-type="fig"}).

FTY720 inhibits adipocyte differentiation of 3T3-L1 cells
---------------------------------------------------------

A decrease in adipose tissue mass can be a result of a decrease in adipocyte size and/or number due to reduction of adipocyte differentiation ([@B14]). Also, FTY720 is phosphorylated *in vivo* by sphingosine kinase 2 to become the active drug metabolite (S)-FTY720-phosphate (FTY-p) and only the (S)-phosphorylated form of FTY720 is capable of activating S1P receptors *in vitro* ([@B4]; [@B53]). Therefore, we studied the influence of FTY-p on adipocyte differentiation in the 3T3-L1 cells. When 3T3-L1 cells were allowed to differentiate over 6 days in the presence of increasing concentrations of FTY-p in the adipogenic medium, a reduction in TG accumulation was observed ([Figures 2A and 2B](#F2){ref-type="fig"}). The effect of FTY-p was significantly detected at 0.1 µM and was maximal at 1 µM.

To confirm the anti-adipogenic differentiation of FTY-p, the mRNA levels of biochemical markers of differentiation (PPARγ, C/EBPα and adiponectin) were determined ([Figures 2C-2E](#F2){ref-type="fig"}). When the 3T3-L1 preadipocytes were differentiated with MDI treatment, the mRNA levels of the adipogenic markers of differentiation increased compared to the control. However, FTY-p treatment led to a significant reduction in the mRNA level of PPARγ, C/EBPα and adiponectin ([Figures 2C-2E](#F2){ref-type="fig"}). The evidence was consistent with an influence of FTY720 on adipocyte differentiation.

Besides altering insulin sensitivity, Akt and its downstream effectors can reduce fat accumulation by reducing adipogenesis *via* GSK3β ([@B41]; [@B5]). To gain insight into the molecular mechanisms responsible for the observed biological effects of FTY-p, the ability of the FTY-p to inactivate Akt was then examined. As illustrated in [Figure 3F](#F3){ref-type="fig"}, MDI containing adipocyte differentiation cocktail decreased the phosphorylation of Akt Ser 473. However, the incorporation of 1 µM FTY-p increased the phosphorylation of Akt (Ser 473). These results showed that FTY-p regulated the phosphorylation of Akt, and so had an anti-adipogenic effect *in vitro*.

FTY720 reduces fat accumulation *via* up-regulation of p-Akt (Ser473) and down-regulation of p-GSK3α/β (Tyr279/216), as well as up-regulation of p-AMPKα (Thr 172)
------------------------------------------------------------------------------------------------------------------------------------------------------------------

As mentioned above, phosphorylation of Akt is important *in vivo* for improving the insulin sensitivity and exerting an anti-obesity effect through a reduction in adipogenesis *via* GSK3β. Akt-mediated inhibition of GSK3β inhibits adipogenesis ([@B41]; [@B50]). Therefore, we detected that the levels of p-Akt (Ser 473) and p-GSK3α/β (Tyr279/216) in HFD-FTY compared with SD and HFD-CON ([Figure 3](#F3){ref-type="fig"}). In mice fed the SD, the level of phosphorylation of Akt (Ser 473) was high, but obesity was declined. The administration of FTY720 showed a dramatic rise of the activation of Akt. Reciprocally, the phosphorylation of GSK3α/β (Tyr279/216) was decreased in SD and HFD induced an incremental increase, but FTY720 tended to decrease it ([Figure 3](#F3){ref-type="fig"}).

Also, phosphorylation of AMPK is pivotal for increasing energy expenditures such as fatty acid oxidation and for inhibiting energy accumulation such as lipogenesis and adipogenic differentiation. The role of AMPK in adipogenesis is not entirely clear, but several AMPK-activating molecules have anti-adipogenic effects *via* MCE inhibition and down-regulation of adipogenic transcriptional pathways ([@B54]). Therefore, we measured the expression of p-AMPKα (Thr 172) in HFD-FTY compared with SD and HFD-CON ([Figures 4A and 4B](#F4){ref-type="fig"}). In mice fed with SD, the level of p-AMPKα (Thr 172) was high, but obesity attenuated it. FTY720 showed a significant rise of the phosphorylation of AMPK. In 3T3-L1 cells, FTY720-p increased the level of phosphorylation of AMPK in a dose-dependent manner as well ([Figures 4C and 4D](#F4){ref-type="fig"}).

These observations supported the view that reduced fat accumulation in FTY720 treated mice is a result of reduced adipogenesis through AMPK and Akt-GSK3α/β pathway.

FTY720 enhances fat breakdown through up-regulation of HSL, ATGL, perilipin and phosphorylation of HSL
------------------------------------------------------------------------------------------------------

Lipolysis in the WAT of humans and rodents is regulated by ATGL, HSL and perilipin ([@B12]; [@B42]). To investigate whether the markedly decreased adiposity observed in HFD-FTY mice was the result of increased lipolysis, we measured the expression of HSL, ATGL and perilipin in gonadal WAT of SD, HFD-CON and HFD-FTY mice. When compared with the WAT of SD, HFD feeding caused significant down-regulations of HSL, ATGL and perilipin mRNA levels ([Figures 5A-5C](#F5){ref-type="fig"}), but FTY720 treatment increased the mRNA levels of HSL, ATGL and perilipin ([Figures 5A-5C](#F5){ref-type="fig"}). The activity of HSL is regulated by both phosphorylation and translocation to the lipid droplet. PKA phosphorylates HSL at Ser 563 ([@B57]; [@B58]). In accordance with these studies, we detected the HSL phosphorylation at Ser 563 in WAT of SD and HFD-FTY mice ([Figures 5D and 5E](#F5){ref-type="fig"}). In SD mice, HSL phosphorylation at Ser 563 in WAT was expressed at high levels, but HFD feeding markedly dropped the phosphorylation of HSL (Ser 563). The HSL phosphorylation at Ser 563 was considerably increased by the administration of FTY720 ([Figures 5D and 5E](#F5){ref-type="fig"}). These results indicated that decreased adiposity in FTY720 treated mice is a result of enhanced lipolysis through the up-regulation of HSL, ATGL and perilipin, as well as phosphorylation of HSL.

FTY720-p increases adipocyte lipolysis of 3T3-L1 cells
------------------------------------------------------

To study the effect of FTY720-p on lipolysis *in vitro*, the differentiated adipocytes were incubated with various concentrations of FTY720-p for 24 h or 1 µM of FTY720-p for various times, and the glycerol level was determined in the medium. FTY720-p treatment led to a significantly higher release of glycerol after the two treatment periods (12 h and 24 h) analyzed ([Figure 6A](#F6){ref-type="fig"}). Also, FTY720-p substantially increased lipolysis in a dose-dependent fashion ([Figure 6B](#F6){ref-type="fig"}).

To assess the effects of FTY720-p on major molecular mechanisms that regulate lipolysis *in vitro*, we examined the phosphorylation of HSL on key serine residues as well as the mRNA content of ATGL, HSL and perilipin. The differentiated adipocytes were incubated with 1 µM of FTY720-p for 12 h and 24 h, and the ATGL, HSL and perilipin mRNA levels were significantly increased ([Figure 6C](#F6){ref-type="fig"}). After 24 h of treatment with 0.1 and 1 µM of FTY720-p, ATGL, HSL and perilipin expression were enhanced in differentiated adipocytes ([Figure 6D](#F6){ref-type="fig"}).

HSL induces lipolysis after phosphorylation of serine residues 563, 659 and 660 ([@B1]; [@B45]; [@B2]), leading to translocation of HSL to lipid droplets and to a marked enhancement of lipolysis. Phosphorylation of perilipin A, a protein associated with the lipid droplet, by protein kinase A (PKA) has also been demonstrated to be necessary for activation of HSL and for catecholamine-induced lipolysis to occur ([@B30]). Conversely, the cellular energy sensor AMPK has been demonstrated to phosphorylate serine-565 of HSL, which prevents PKA-mediated phosphorylation of this enzyme and impairs catecholamine-stimulated lipolysis ([@B13]). While phosphorylation of HSL at Ser 563 was increased, phosphorylation of HSL at Ser 565 was dose-dependently decreased by FTY720-p ([Figures 6E and 6F](#F6){ref-type="fig"}). The effect of FTY720-p was significantly detected at 1 µM from 4 h and was prolonged to 48 h ([Figures 6E and 6F](#F6){ref-type="fig"}). These results revealed the pro-lipolytic activity of FTY720-p *in vitro*.

Discussion
==========

The data presented here show for the first time that FTY720 acts as an anti-obesity drug, which induces resistance to HFD-induced obesity and that the action of FTY720 is mediated by both anti-adipogenic differentiation and pro-lipolytic action. Administration of FTY720 to HFD-induced obese mice effectively reduced body weights as well as body fat mass by increasing anti-adipogenic action *via* the regulation of Akt-GSK 3α/β signaling and diminished lipolysis *via* regulation of HSL. *in vitro*, treatment with exogenous FTY720-p effectively inhibited adipogenesis by down-regulating the expression of adipocyte specific differentiation markers. Moreover, treatment with exogenous FTY720-p significantly enhanced lipolysis by up-regulating the expression and phosphorylation of HSL, ATGL and perilipin.

Excessive adipose tissue accumulation is a result of an increase in both adipocyte number (hyperplasia) that occurs through adipocyte differentiation and adipocyte size (hypertrophy) that occurs when triacylglycerol synthesis exceeds breakdown (lipolysis). From this perspective, FTY720 might behave as a novel anti-obesity drug, because FTY720 effectively prevented HFD-induced obesity, both by blocking the adipocyte number and adipocyte size that through anti-adipogenic action and pro-lipolytic action, respectively.

FTY720 was originally derived as an immunomodulatory compound exerting beneficial effects in several animal models of chronic inflammation ([@B4]; [@B6]). A large number of preclinical studies have demonstrated the efficacy of FTY720 in models of organ transplantation, autoimmune disease and cancer ([@B4]). FTY720 has focused over only immune suppression or proliferation, so we investigated other action of FTY720. Recently, consistent with our results ([Figure 1](#F1){ref-type="fig"}), a new study found that FTY720 administration prevents HFD-induced weight gain, insulin resistance and adipose tissue inflammation ([@B22]). Moreover, this report revealed that resistance to HFD-induced obesity was caused by reduction of adipose tissue lympohcytes and macrophages, as well as the favoring of a CD11c-negative, anti-inflammatory macrophage phenotype, because adipose tissue activated macrophages and lymphocytes contribute to insulin resistance through the secretion of factors that impair insulin signaling ([@B46]; [@B22]). However, the study only clarified that FTY720 reduced adipose tissue lymphocytes and macrophages, as well as favoring a CD11c-negative, anti-inflammatory macrophage phenotype and focused on only immune modulating function of FTY720 ([@B22]). Furthermore, the administration dose of FTY720 (0.04 mg/kg twice per week) we used has been shown not to alter the leukocyte profile or the B-cell counts ([@B34]). Our results presented here show for the first time previously unknown actions of FTY720, as a negative regulator of adipocyte differentiation ([Figure 2](#F2){ref-type="fig"}) *via* the up-regulation of p-Akt ([Figures 2F](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}) and a positive regulator of lipolysis ([Figures 5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"}) *in vivo* as well as *in vitro*.

Akt is related to lipogenesis. HFD-induced hepatic steatosis is correlated with decreased Akt phosphorylation upon insulin treatment ([@B36]). Skeletal muscle-specific overexpression of Akt 1 reduces fat accumulation while increasing fatty acid oxidation in the liver with less steatosis ([@B17]). Akt/mTOR-mediated skeletal muscle hypertrophy ([@B39]) leads to increased insulin sensitivity ([@B17]), which may be physiologically associated with the alterations in insulin sensitivity of FTY720-treated mice. Moreover, GSK3β is adipogenic ([@B41]) so its inhibition in FTY720 administration mice may contribute to their leanness. Thus, the role of Akt in lipogenesis is complex and may reflect isoformand tissue-specific effects.

The molecular machinery involved in triacylglycerol breakdown and fatty acid release works in an orderly and regulated fashion, conferring to WAT the capacity to respond to various feeding conditions and to the energy demands of the body ([@B12]). Importantly, conditions that lead to overeating and obesity disrupt normal regulation of WAT lipolysis. In fact, basal lipolysis has repeatedly been reported as elevated, whereas catecholamine-induced lipolysis is suppressed in obese humans and rodents ([@B59]; [@B20]). The classical mechanism to explain this condition is centered on the fact that the largely expanded WAT of obese subjects becomes resistant to insulin, impairing the major lipogenic and antilipolytic effects of this hormone ([@B38]; [@B59]; [@B2]; [@B48]; [@B12]). In HFD-induced obese mice, HSL and perilipin content are severely reduced ([@B12]). In line with this report, presently HSL and perilipin mRNA levels were seriously decreased and phosphorylation of HSL at Ser 563 was also markedly reduced in HFD-CON, but FTY720 reversed the content of HSL and perilipin and phosphorylation of HSL at Ser 563 in WAT ([Figure 5](#F5){ref-type="fig"}). Also, FTY720 had effect on inducing lipolysis *in vitro*. FTY720-p treatment time- and dose-dependently increased glycerol release, lipolytic related gene expression and phosphorylation of HSL at Ser 563. Although increased lipolysis in HFD feeding led to the release of FFA to serum, resulting in insulin resistance terminally, other mouse models displaying increased lipolysis and decreased adipose tissue mass also reported unchanged or reduced serum non-esterified fatty acid ([@B29]; [@B51]; [@B27]; [@B16]; [@B19]). Despite increased lipolysis resulted in ectopic triacylglycerol accumulation in the liver and skeletal muscle, oxygen consumption is increased and Ucp1, Dio2 and Ppard mRNA expression in WAT is substantially increased, suggesting higher oxidation and thermogenesis in WAT ([@B19]). Moreover, AMPK has been shown to increase fatty acid oxidation in WAT. AMPK stimulates pathways, which increase fatty acid oxidation ([@B8]). Presently, HFD decreased the phosphorylation of AMPK, but FTY720 increased the phosphorylation of AMPK in WAT ([Figure 4](#F4){ref-type="fig"}). Therefore, we propose that FTY720 might increase energy production (glucose transport, fatty acid oxidation).

In conclusion, the results of this study show that exposure of HFD-induced obese mice to FTY720 inhibits the development of obesity. There are two suggested mechanisms of FTY720 to resistance to obesity. First, FTY720 inhibits adipogenesis *in vitro* as well as *in vivo*, as confirmed by a reduction in triglyceride accumulation, a reduction in the expression of adipocyte specific genes and regulating Akt pathways. Secondly, FTY720 enhances lipolysis *in vitro* as well as *in vivo*, as confirmed by an increase in glycerol release and lipolysis-associated gene expressions.

This is the first study to identify the anti-obesity action of FTY720 by the modulation of adipogenesis and lipolysis. These results suggest that FTY720 might be therapeutic for obesity.

Methods
=======

Animals
-------

All studies received approval from the Chonbuk University laboratory animal research center. We used mice on a pure C57BL/6J background. In total, 20 male and 5-week-old C57BL/6J mice initially weighing 20-22 g obtained from Samtako biokorea (Osan, Korea). The animal room was maintained at 23 ± 1℃ with alternating 12-h light and dark cycles. After a 1-week acclimatization period, 20 mice were divided randomly into two groups. The normal group was fed with a standard diet (SD), whereas the model group was fed with a HFD. The SD was composed of 10 kcal% fat, 70 kcal% carbohydrates and 20 kcal% protein, whereas the HFD was composed of 45 kcal% fat, 35 kcal% carbohydrate, and 20 kcal% protein) (%kcal of total energy). After 3 weeks of feeding with the HFD, the resulting obese mice were subdivided randomly into three groups consisting of five mice each. One was an obese control model group. In the second group, mice were injected intraperitoneally (i.p.) with FTY720 (0.04 mg/kg in phosphate buffered saline (PBS) twice a week for 6 weeks). In both groups, body weight was measured weekly. The third group was administered the same volume (0.1 ml) of only the PBS vehicle. Whole body fat composition of live animals was determined after the treatment period using a Minispec nuclear magnetic resonance analyzer (Bruker Optics, Billerica, MA). The epididymal fat-pad samples were stored at -70℃ until they were analyzed. All animal procedures were performed in accordance with the institutional guidelines for the Chonbuk University laboratory animal research center.

Reagents
--------

FTY720 was purchased from Cayman Chemical (Ann Arbor, MI). FTY720 phosphate (FTY720-p) was purchased from Echelon Biosciences (Salt Lake City, UT). FTY720 was prepared as a 1 mg/ml solution in PBS. FTY720-p was prepared as a 2 mM solution in methanol and then further diluted in cell culture medium.

Cell culture and differentiation
--------------------------------

The 3T3-L1 cells were maintained in Dulbecco\'s modified Eagle\'s medium (DMEM) containing 10% calf serum and antibiotics (100 µg·ml^-1^ gentamycin and 100 µg·ml^-1^ penicillin-streptomycin). To induce differentiation, 2-day postconfluent 3T3-L1 cells were incubated in MDI induction media (DMEM containing 10% fetal bovine serum, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 1 µm dexamethasone and 1 µg/ml of insulin) for 2 days. In some experiments, FTY720-p (1 µM) was added at the time of the induction of differentiation. Two days after MDI (DAY 2) the media was changed to insulin media.

Quantification of lipid content
-------------------------------

Lipid content was quantified using AdipoRed Assay Reagent (Lonza, Verviers, Belgium) according to the manufacturer\'s instructions. In brief, preadipocytes grown in 24-well plates were incubated with MDI medium alone or medium + test compounds during the adipogenic phase and, on day 7. The wells were then filled with 300 µl PBS and 30 µl of Adipored reagent was added and incubated for 10 min at 37℃. Fluorescence was measured with an excitation and emission wavelength of 485 nm and 572 nm, respectively.

Adipolysis assay
----------------

Glycerol release was measured using the Adipolysis Assay Kit (Cayman Chemical) according to the manufacturer\'s instructions. Briefly, differentiated adipocytes in a 96-well plate were stimulated with FTY720-p for 24 h. After stimulation, the cell culture supernatants were collected from each well and stored until use at -20℃. One hundred microliters of free glycerol assay reagent was added to 25 µl of each supernatant. After incubation for 15 min at room temperature, the absorbance was measured at 540 nm.

Quantitative real-time polymerase chain reaction (qRT-PCR)
----------------------------------------------------------

Total RNA was extracted from 3T3-L1 cells treated with S1P using the Easy-spin™ total RNA extraction kit (iNtRON Biotechnology, Seoul, Korea). cDNA synthesis was carried out following the instructions of the Prime Script™ 1st strand cDNA synthesis kit (TaKaRa Bio, Tokyo, Japan). For qRT-PCR, 1 µl of gene primers with SYBR Green (Bio-Rad Laboratories, Hercules, CA) in 20 µl of reaction volume was applied. The sequences of the primers used for the Real-time PCR were as follows:

PPARγ (forward 5\'CGGAAGCCCTTTGGTGACTTTATG3\', reverse 5\'GCAGCAGGTTGTCTTGGATGTC3\'), C/EBP-α (forward 5\'CGGGAACGCAACAACATCGC3\', reverse 5\'TG TCCAGTTCACGGCTCAGC3\'), Adiponectin (forward 5\'TG ACGGCAGCACTGGCAAG3\', reverse 5\'TGATACTGGTCG TAGGTGAAGAGAAC3\') ATGL (forward 5\'GAGCTTCGCG TCACCAAC3\', reverse 5\'CACATCTCTCGGAGGACCA3\'), HSL (forward 5\'AGACCACATCGCCCACA3\', reverse 5\'CC TTTATTGTCAGCTTCTTCAAGG3\'), Perilipin (forward 5\'C ACTCTCTGGCCATGTGGA3\', reverse 5\'AGAGGCTGCCA GGTTGTG3\') and β-actin (forward 5\'TGAGAGGGAAATCG TGCGTGAC3\', reverse 5\'GCTCGTTGCCAATAGTGATGA CC3\').

All reactions with iTaq SYBR Green Supermix (Bio-Rad Laboratories) were performed on the CFX96 real-time PCR detection system (Bio-Rad Laboratories).

Western blot
------------

The 3T3-L1 cells were lysed in a lysis buffer (25 mM HEPES; pH 7.4, 100 mM NaCl, 1 mM EDTA, 5 mM MgCl~2~, 0.1 mM dithiothreitol and protease inhibitor mixture). Proteins were electrophoretically resolved by 8-15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting was performed as previously described ([@B31]). Images were captured using the Fusion FX7 acquisition system (Vilbert Lourmat, Eberhardzell, Germany) ([@B43]). The antibodies used for immunoblotting were p-Akt (Ser 473) (Epitomics, Burlingame, CA), p-GSK3α/β (Tyr279/216) (Santa Cruz Biotechnology, Santa Cruz, CA), p-HSL (Ser 563) (Cell Signaling Technology, Beverly, MA), p-HSL (Ser 565) (Cell Signaling Technology) and β-actin (Sigma-Aldrich, St. Louis, MO).

Statistical evaluation
----------------------

All data are expressed as the mean ± SEM, and the data were compared using the Student\'s *t*-test and the ANOVA Duncan test with the SAS statistical package. The results were considered significant for values of ^\*^*P* \< 0.05 or ^\*\*^*P* \< 0.01.

This study was supported by the National Research Foundation of the Korea Grant funded by the Korean Government (2012R1A1B3000463) and partially supported by research funds of Chonbuk National University in 2012.
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![FTY720 administration mice are resistant to obesity. (A) Gross appearance of standard diet (*n* = 5, SD) and high fat-diet (*n* = 6, HFD) fed mice. (B) Time course of body weights over 15 weeks in mice fed a SD and HFD. (C) Gross appearance of HFD controls (*n* = 6, CON), PBS-treated (*n* = 6, PBS) and FTY720-treated (*n* = 6, FTY) obese mice. (D) Time course of body weights over 15 weeks in mice fed with HFD and intraperitoneally injected with none (*n* = 6, CON), PBS-treated (*n* = 6, PBS) and FTY720-treated (*n* = 6, FTY). (E, F) Average body weights (E), epididymal fat pad weights (F) and organ weights (G) of mice at 15 weeks. (H, I) Representative images (H) of hematoxylin and eosin-stained sections of gonadal WAT and adipocyte cell size (I) in gonadal WAT. (J, K) Body fat composition of HFD controls (*n* = 6, CON), PBS-treated (*n* = 6, PBS) and FTY720-treated (*n* = 6, FTY) obese mice was calculated percent of CON. Data are expressed as the means ± SD for 6 mice. ^\*^*P* \< 0.05; and ^\*\*^*P* \< 0.01, significant differences between HFD control and each treatment group; ^\#\#^*P* \< 0.01, significant differences between PBS treatment group and FTY720 treatment group.](emm-44-603-g001){#F1}

![FTY720 phosphate (FTY-p) decreases lipid droplets during the differentiation of 3T3-L1 preadipocytes. (A) Preadipocytes were induced to differentiate with FTY-p of increasing concentrations for 6 days. The AdipoRed assays were performed on day 6 and were photographed with a light microscope (× 200). (B) Fluorescence was measured with an excitation wavelength of 485 nm and an emission wavelength of 572 nm. Bar graph indicates the mean ± S. E. M. (*n* = 3). The experiments were repeatedly performed to confirm the results. The data were analyzed using analysis of variance (ANOVA) and Duncan multiple range test (*P* \< 0.05). Means sharing a common alphabetical symbol do not differ significantly. (C-E) Preadipocytes were induced to differentiate with FTY-p (1 µM) and harvested at day 7 during the differentiation period. The mRNA expression of PPARγ (C), C/EBPα (D) and adiponectin (E) was analyzed by real-time RT-PCR. Values are mean ± S. E. M. of data from three separate experiments (*n* = 3); each experiment was performed in triplicate. The data were analyzed using analysis of variance (ANOVA) and Duncan multiple range test (*P* \< 0.05). Means sharing a common alphabetical symbol do not differ significantly. (F) Preadipocytes were induced to differentiate with or without FTY-p 0.1 and 1 µM for 2 days. At day 2, the protein levels of p-Akt were analyzed by Western blot. The experiments were repeatedly performed to confirm the results.](emm-44-603-g002){#F2}

![FTY720 induces Akt phosphorylation and inhibits the activation of GSK-3α/β. (A) Western blot analysis for p-Akt (Ser 473) (Upper panel) and p-GSK-3α/β (Tyr279/216) (middle panel) protein in WAT of standard diet (*n* = 3, SD), high fat-diet (*n* = 5, HFD CON) and FTY720-treated obese mice (*n* = 5, HFD FTY720). (B) Levels of p-Akt (Ser 473) and p-GSK-3α/β (Tyr279/216) were normalized to α-actin. The experiments were repeatedly performed to confirm the results. The data were analyzed using student\'s t-test. ^\*\*^*P* \< 0.01, significant differences between SD and each treatment group; ^\#\#^*P* \< 0.01, significant differences between HFD-CON and HFD-FTY720 group.](emm-44-603-g003){#F3}

![FTY720 induces AMPK phosphorylation *in vivo* as well as *in vitro*. (A) Western blot analysis for p-AMPK (Thr 172) protein in WAT of standard diet (*n* = 4, SD), high fat-diet (*n* = 5, HFD CON) and FTY720-treated obese mice (*n* = 5, HFD FTY720). (B) Levels of p-AMPK (Thr 172) were normalized to α-actin. The experiments were repeatedly performed to confirm the results. The data were analyzed using student\'s t-test. ^\*\*^*P* \< 0.01, significant differences between SD and each treatment group; ^\#\#^*P* \< 0.01, significant differences between HFD-CON and HFD-FTY720 group (C) Preadipocytes were induced to differentiate with or without FTY-p 0.1, 1 and 10 µM for 4, 12 and 24 h. At indicated hours, the protein levels of p-AMPK were analyzed by Western blot. The experiments were repeatedly performed to confirm the results. (D) Level of p-AMPK was normalized to α-actin. The experiments were repeatedly performed to confirm the results. The data were analyzed using Student\'s t-test. ^\*\*^*P* \< 0.01, significant differences between control and each treatment group.](emm-44-603-g004){#F4}

![FTY720 up-regulates ATGL, HSL, perilipin gene expression as well as activation of HSL. (A-C) Relative mRNA levels were measured by RT-qPCR for the ATGL (A), HSL (B) and perilipin (C) genes from WAT of SD, HFD-CON and HFD-FTY mice. (D) Western blot analysis for the phosphorylation status of Ser 563 of HSL in WAT of SD (*n* = 4, SD), high fat-diet (*n* = 5, HFD CON) and FTY720-treated obese mice (*n* = 5, HFD FTY720). (E) Levels of p-HSL (Ser 563) was normalized to α-actin using densitometry. The experiments were repeatedly performed to confirm the results. The data were analyzed using student\'s t-test. ^\*\*^*P* \< 0.01, significant differences between SD and each treatment group; ^\#\#^*P* \< 0.01, significant differences between HFD-CON and HFD-FTY720 group.](emm-44-603-g005){#F5}

![FTY720-p increases lipolysis as well as ATGL, HSL, perilipin mRNA levels and the activation of HSL in differentiated adipocytes. (A, B) Differentiated adipocytes were stimulated with indicated time (A) for 1 µM of FTY720-p or indicated concentrations (B) of FTY720-p for 24 h. The concentration of glycerol in the medium determined as described in Materials and Methods. (C, D) Differentiated adipocytes were stimulated with indicated time (C) with 1 µM FTY720-p or indicated concentrations (D) of FTY720-p for 24 h. Then, relative mRNA levels were measured by RT-qPCR for ATGL, HSL and perilipin. Bar graph indicates the mean ± S. E. M. (*n* = 3). ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01, significant differences between control and each treatment group; ^\#\#^*P* \< 0.01, significant differences between control and each treatment group; ^\$\$^*P* \< 0.01, significant differences between control and each treatment group. (E) Western blot analysis for p-HSL (Ser 563) (Upper panel) and p-HSL (Ser 565) (middle panel) protein in differentiated adipocytes treated with 1 µM FTY720-p for 4 h, 24 h or 48 h. Methanol was used as vehicle control. (F) Levels of p-HSL (Ser 563) and p-HSL (Ser 565) were normalized to α-actin. The experiments were repeatedly performed to confirm the results. The data were analyzed using Student\'s t-test. ^\*^*P* \< 0.05 and ^\*\*^*P* \< 0.01, significant differences between S. E. M. and each treatment group; ^\#\#^*P* \< 0.01, significant differences between HFD-CON and HFD-FTY720 group.](emm-44-603-g006){#F6}
